The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation

Carcinogenesis

Volumn 19, Issue 5, 1998, Pages 861-866

  Davis, Warren ^a   Venitt, Stan ^a   Phillips, David H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; COLLAGENASE; DIMETHYL SULFOXIDE; HYDROXYTAMOXIFEN; MAGNESIUM SULFATE; PHOSPHORUS 32; PRASTERONE SULFATE; SOLVENT; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACTIVATION; DRUG DNA BINDING; DRUG SULFATION; FEMALE; LIVER CELL CULTURE; LIVER PERFUSION; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOTRANSFORMATION; CELLS, CULTURED; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; LIVER; RATS; RATS, INBRED F344; SULFATES; TAMOXIFEN;

EID: 0031867191     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/19.5.861     Document Type: Article

References (40)

1. Fisher,B., Costantino,J.P., Redmond,C.K., Fisher,E.R., Wickerham,D.L. and Cronin,W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
2. van Leeuwen,F.E., Benraadt,J., Coebergh,J.W.W. et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343, 448-452.
3. Williams,G.M., Iatropoulos,M.J., Djordjevic,M.V. and Kaltenberg,O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
4. Greaves,P., Goonetilleke,R., Nunn,G., Topham,J. and Orton,T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
5. Hirsimaki,P., Hirsimaki,Y., Nieminen,L. and Payne,B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol., 67, 49-54.
6. Davies,R., Oreffo,V.I.C., Martin,E.A., Festing,M.F.W., White,I.N.H., Smith,L.L. and Styles,J.A. (1997) Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res., 57, 1288-1293.
7. Rajah,T.T. and Pento,J.T. (1995) The mutagenic potential of antiestrogens at the HPRT locus in V79 cells. Res. Comm. Path. Pharm., 89, 85-92.
8. Han,X. and Liehr,J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
9. White,I.N.H., de Matteis,F., Davies,A., Smith,L.L., Crofton-Sleigh,C., Venitt,S., Hewer,A. and Phillips,D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-203.
10. Sargent,L.M., Dragan,Y.P., Sattler,C. et al. (1996) Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis, 17, 1051-1056.
11. Crofton-Sleigh,C., Doherty,A., Ellard,S., Parry,E.M. and Venitt,S. (1993) Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase. Mutagenesis, 8, 363-372.
12. Phillips,D.H., Hewer,A., Grover,P.L., Poon,G.K. and Carmichael,P.L. (1996) Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149-1152.
13. Hemminki,K., Rajaniemi,H., Koskinen,M. and Hansson,J. (1997) Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. Carcinogenesis, 18, 9-13.
14. Carmichael,P.L., Ugwumadu,A.H., Neven,P., Hewer,A.J., Poon,G.K. and Phillips,D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
15. Hemminki,K., Rajaniemi,H., Lindahl,B. and Moberger,B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
16. Dehal,S.S. and Kupfer,D. (1996) Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res., 56, 1283-1290.
17. Pongracz,K., Pathak,D.N., Nakamura,T., Burlingame,A.L. and Bodell,W.J. (1995) Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation by tamoxifen. Cancer Res., 55, 3012-3015.
18. Pathak,D.N., Pongracz,K. and Bodell,W.J. (1996) Activation of 4-hydroxytamoxifen and tamoxifen derivative E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 17, 1785-1790.
19. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
20. Pathak,D.N., Pongracz,K. and Bodell,W.J. (1995) Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 16, 11-15.
21. Moorthy,B., Sriram,P., Pathak,D.N., Bodell,W.J. and Randerath,K. (1996) Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57.
22. Potter,G.A., McCague,R. and Jarman,M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442.
23. 5-ethyl]-tamoxifen implicates a-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis, 15, 1487-1492.
24. Phillips,D.H., Carmichael,P.L., Hewer,A., Cole,K.J. and Poon,G.K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
25. Phillips, D.H., Carmichael,P.L., Hewer,A., Cole,K.J., Hardcastle,I.R., Poon,G.K., Keogh,A. and Strain,A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94.
26. Osborne,M.R., Hewer,A., Hardcastle,I.R., Carmichael,P.L. and Phillips,D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
27. 5-ethyl]tamoxifen. Carcinogenesis, 16, 683-688.
28. Randerath,K., Bi,J., Mabon,N., Sriram,P. and Moorthy,B. (1994) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environment pollutant pentachlorophenol. Carcinogenesis, 15, 797-800.
29. Berry,M.N., Edwards,A.M. and Barritt,G.J. (1991) Isolated hepatocytes. Preparation, properties and application. In Burdon,R.H. and van Kippenburg,P.H. (eds) Laboratory Techniques in Biochemistry and Molecular Biology, vol. 21. Elsevier, Amsterdam.
30. Gupta,R.C. (1984) Non-random binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc. Natl Acad. Sci USA, 81, 6943-6947.
31. 32P-postlabelling test for structurally diverse DNA adducts. Carcinogenesis, 7, 1543-1551.
32. Michejda,C.J. and Kroeger-Koepke,M.B. (1994) Carcinogen activation by sulphate conjugate formation. In Anders,M.W. and Dekant,W. (eds) Conjugation-dependent Carcinogenicity and Toxicity of Foreign Compounds, vol. 27. Academic Press, San Diego, pp. 331-363.
33. Falany,C.N. and Wilborn,T.W. (1994) Biochemistry of cytosolic sulfotransferases involved in bioactivation. Adv. Pharmacol., 27, 301-329.
34. Sharp,S., Barker,E.V., Coughtrie,M.W.H., Lowenstein,P.R. and Hume,R. (1993) Immunochemical characterisation of a dehydroepiandrosterone sulfotransferase in rats and humans. Eur. J. Biochem., 211, 539-548.
35. Watabe,T., Hiratsuka,A. and Ogura,K. (1987) Sulphotransferase-mediated covalent binding of the carcinogen 7,12-dihydroxymethylbenz[a] anthracene to calf thymus DNA and its inhibition by glutathione transferase. Carcinogenesis, 8, 445-453.
36. Werner,S., Kunz,S., Wolff,T. and Schwarz,L.R. (1996) Steroidal drug cyproterone acetate is activated to DNA-binding metabolites by sulfonation. Cancer Res., 56, 4391-4397.
37. Dasaradhi,L. and Shibutani,S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Taxicol., 10, 189-196.
38. Okuda,H., Nojima,H., Watanabe,N. and Watabe,T. (1989) Sulphotransferase-medialed activation of the carcinogen 5-hydroxymethyl-chrysene. Species and sex differences in tissue distribution of the enzyme activity and a possible participation of hydroxysteroid sulphotransferases. Biochem. Pharmacol., 38, 3003-3009.
39. Surh,Y.J., Liem,A., MillerE.C. and Miller,J.A. (1991) Age-and sex-related differences in activa,tion of the carcinogen 7-hydroxymethyl-12-methylbenz[a]anthracene to an electrophilic sulfuric acid ester metabolite in rats. Possible involvement of hydroxysteroid sulfotransferase activity. Biochem. Pharmacol., 41, 213-221.
40. Shinohara,A., Saito,K., Yamazoe,Y., Kamataki,T. and Kato,R. (1986) Inhibition of acetyl-coenzyme A dependent activation of N-hydroxyarylamines by phenolic compounds, pentachlorophenol and 1-nitro-2-naphthol. Chem.-Biol. Interactions, 60, 275-285.